BioSpace News Archive

The results from the trial will serve as the basis of the Company’s regulatory submission to the CFDA to gain approval to commercialize BioGlue in China. Patients are currently being enrolled at multiple heart centers in China.

Impax Labs announced today that it has received the consents necessary to amend and insert certain provisions in the indenture dated as of June 30, 2015 between the Company and Wilmington Trust, National Association, as trustee, governing its 2.00% Convertible Senior Notes due 2022.

This exciting news comes only months after bringing into operation Avecia’s new API manufacturing synthesis capabilities.

This agreement is an extension of the recently announced partnership between CURE, Therapix and Israel’s Assuta Medical Centers, Ltd.

The poster’s authors include scientists from the laboratories of Professor John Williams of the Beckman Research Institute at the City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University, along with Dr. Margaret Karow, Senior Vice President of Drug Discovery and Preclinical Development at Akriveia Therapeutics.

As described in the offering circular published by Orphazyme A/S on 6 November 2017, the Company applied to the FDA for the designation in September 2017.

ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types.

CB-839 is an orally bioavailable glutaminase inhibitor currently in Phase 2 trials, and Opdivo® is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.

The data being presented at the 2017 ACR/AHRP) show that weekly treatment with BENLYSTA SC 200mg reduced the need to increase the dose of corticosteroid (one standard of care medication for patients with SLE).

The study was designed to compare the profile of DM199 to that of the approved urinary KLK1 product (trade name Kailikang) on the market in Asia for acute ischemic stroke.